Evidence map›Paper›PMID 41229406›Full record

ArticleNeuropsychiatric disease and treatment2025

Hui Liu, Gaojie Liu, Yuxuan Zhang, Weicai Suo, Yan Hao, Yizhong Wang, Hongfang Ding

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hui Liu *Department of Pediatrics, Shengli Oil Field Central Hospital, Binzhou Medical University, Dongying, Shandong, People's Republic of China.
Gaojie Liu *Gut Microbiota and Metabolic Research Center, Institute of Pediatric Infection, Immunity and Critical Care Medicine, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Yuxuan Zhang *Department of Pediatrics, Shengli Oil Field Central Hospital, Binzhou Medical University, Dongying, Shandong, People's Republic of China.ORCID 0009-0002-2845-1818
Weicai SuoDepartment of Pediatrics, Shengli Oil Field Central Hospital, Binzhou Medical University, Dongying, Shandong, People's Republic of China.
Yan HaoGut Microbiota and Metabolic Research Center, Institute of Pediatric Infection, Immunity and Critical Care Medicine, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Yizhong WangGut Microbiota and Metabolic Research Center, Institute of Pediatric Infection, Immunity and Critical Care Medicine, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.ORCID 0000-0002-9390-8864
Hongfang DingDepartment of Pediatrics, Shengli Oil Field Central Hospital, Binzhou Medical University, Dongying, Shandong, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Compelling evidence has confirmed that gut microbiota dysbiosis is involved in the development of autism spectrum disorder (ASD). Microbial-based therapies, including probiotics, may provide novel options for ASD management. This study aimed to investigate the alleviative effect of a probiotic strain, Methods: Male offspring of VPA-exposed pregnant Sprague-Dawley rats treated with Results: Conclusion: These findings reveal that

Indexed as

ASDBifidobacterium adolescentisgut microbiotaprobioticSCFAs

Identifiers

PMID41229406
PMCPMC12604599

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.